Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Gov't Grants Med BioGene $262K to Develop CVD Biomarkers

NEW YORK (GenomeWeb News) — Diagnostics developer Med BioGene has received a CA$307,000 ($262,000) grant from the Canadian government to develop biomarkers to help physicians detect and manage cardiovascular disease, the company said Friday.
 
The grant came from the National Research Council Canada Industrial Assistance Program.
 
MBI, based in Vancouver, BC, said it is working with CVD patient samples provided by the University of Ottawa Heart Institute to confirm its biomarkers.
 
Company President and CSO Nathan Yoganathan said he expects genetic biomarkers for CVD to be "an invaluable tool for periodic screening" for high-risk patients, or patients with early, mid-, or late-stage CVD.
 
Yoganathan said such a diagnostic would be a "first step" for cardiologists, who may then pursue more specific tests on patients found to be at risk. The test also could be used to prevent patients not at risk from undergoing “unnecessary and invasive testing," Yoganathan said.
 
MBI said it uses its gene expression-profiling system to develop and validate biomarkers for cardiovascular disease, lymphoma, and leukemia.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.